Novel Mechanisms for Post-Transplant Maintenance Therapy in Acute Myeloid Leukemia.
Publication/Presentation Date
1-1-2022
Abstract
Allogeneic stem cell transplantation has improved survival for patients with acute myeloid leukemia (AML), especially for patients with disease at high risk of relapse. However, relapse remains the most common cause of treatment failure and death in the post-transplant period. Maintenance therapy, an extended course of treatment after achieving remission to reduce the rate of relapse, is an important component of the treatment of various hematologic malignancies; however, its role in the treatment of AML is far less well-defined. Recently, there has been significant interest in the use of novel therapeutic agents as maintenance therapy after allogeneic stem cell transplant, utilizing new mechanisms of treatment and more favorable toxicity profiles. In this review, we will discuss the mechanistic and clinical data for post-transplant maintenance therapies in AML. Then, we will review several emergent and current clinical trials which aim to incorporate novel agents into maintenance therapy regimens.
Volume
12
First Page
892289
Last Page
892289
ISSN
2234-943X
Published In/Presented At
Manobianco, S. A., Rakiewicz, T., Wilde, L., & Palmisiano, N. D. (2022). Novel Mechanisms for Post-Transplant Maintenance Therapy in Acute Myeloid Leukemia. Frontiers in oncology, 12, 892289. https://doi.org/10.3389/fonc.2022.892289
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
35912243
Department(s)
Administration and Leadership
Document Type
Article